English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 13.39 |
| Open | 13.19 |
| 1-Year Change | -42.75% |
| Day's Range | 13.04 - 13.62 |
Viridian Therapeutics, Inc. (Viridian) is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company’s products include VRDN-001 and VRDN-002. The Company’s advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R). The IGF-1R is a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. The Company’s product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. The VRDN-002 is designed to support the administration as a convenient, low-volume, subcutaneous injection.
BRIEF: For the fiscal year ended 31 December 2021, Viridian Therapeutics Inc revenues increased from $1.1M to $3M. Net loss decreased 28% to $79.4M. Revenues reflect Collaboration revenue increase from $735K to $3M. Lower net loss reflects Acquired in-process research and develop decrease from $69.9M (expense) to $0K, Interest and other expense decrease of 99% to $3K (expense), Interest and other income increase of 84% to $318K (income).
